Home           Contact us           FAQs           
 
   Journal Page   |   Aims & Scope   |   Author Guideline   |   Editorial Board   |   Search
    Abstract
2009 (Vol. 1, Issue: 2)
Article Information:

Probable Cure of Two Patients With Advanced Gastric Carcinoma by Chemotherapy Only: Long-term Follow-up of a Phase I Trial With a Weekly Carboplatin and Epirubicin Regimen

E.J.M. Siemerink, G.A.P. Hospers, J.C. Berends, J.A. Gietema and N.H. Mulder
Corresponding Author:  Mulder 

Key words:  Stomach neoplasms, metastatic, chemotherapy, gastric, long-term survival, ,
Vol. 1 , (2): Page No: 42-46
Submitted Accepted Published
2009 Month, 00 2009 July, 18
Abstract:

A dose escalation study of carboplatin in combination with 5FU and epirubicin in surgically incurable gastric cancer. Carboplatin was combined with a fixed dose epirubicin 35 mg/m2, leucovorin 250 mg/m2 and 5 FU 500 mg/m2 (CELF). The starting dose of carboplatin w as 100 mg/m2 which was escalated to 150 mg/m2. This CELF regimen was repeated every week, for a maximum of 14 cycles. Primary prophylaxis against leucopenia with filgastrim w as given. Twelve chemotherapy naive patients were enrolled, 9 w ith metastatic disease and 3 with locally advanced surgically irresectable disease. The major toxicities of the CELF regimen were uncomplicated leucopenia and thrombopenia. Nausea and mucositis were the most common nonhematological toxicities. The dose-limiting toxicity was grade 3 leucopenia, observed at a dose of 150 mg/m2/week. The objective response rate was 58% (95% CI 31%-85%). From the three patients with localized but surgically incurable disease two remain alive without disease progression and without sym ptoms after 6 and 9 years after chemotherapy without any other treatment.
Abstract PDF HTML
  Cite this Reference:
E.J.M. Siemerink, G.A.P. Hospers, J.C. Berends, J.A. Gietema and N.H. Mulder, 2009. Probable Cure of Two Patients With Advanced Gastric Carcinoma by Chemotherapy Only: Long-term Follow-up of a Phase I Trial With a Weekly Carboplatin and Epirubicin Regimen.  Asian Journal of Medical Sciences, 1(2): Page No: 42-46.
    Advertise with us
 
ISSN (Online):  2040-8773
ISSN (Print):   2040-8765
Submit Manuscript
   Current Information
   Sales & Services
   Contact Information
  Executive Managing Editor
  Email: admin@maxwellsci.com
  Publishing Editor
  Email: support@maxwellsci.com
  Account Manager
  Email: faisalm@maxwellsci.com
  Journal Editor
  Email: admin@maxwellsci.com
  Press Department
  Email: press@maxwellsci.com
Home  |  Contact us  |  About us  |  Privacy Policy
Copyright © 2009. MAXWELL Science Publication, a division of MAXWELLl Scientific Organization. All rights reserved